Nutex Health, Inc.
NASDAQ:NUTX · NASDAQ Capital Market
+$2.84 today
Vol 0.14M · Avg 0.17M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
21.5%
avg 17.9%
ROIC
25.9%
avg 117.2%
ROA
7.7%
avg -188.8%
Analysis
ROIC is currently the strongest return metric at 25.9% versus its period average of 117.2%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Thomas T. Vo | Chairman of the Board & Chief Executive Officer | $1.53M | — | 53 | $2.10M | 35.32% |
Warren Hosseinion | President & Director | $1.20M | — | 54 | $7,765.00 | 0.13% |
Jon C. Bates | Chief Financial Officer | $684,536.00 | — | 55 | $5,527.00 | 0.09% |
Michael Chang | Chief Medical Officer | $549,097.00 | — | 54 | $1,426.00 | 0.02% |
Wesley Bamburg FACHE | Chief Operating Officer | $392,722.00 | — | — | $2,411.00 | 0.04% |
Pamela W. Montgomery | Chief Legal Officer of Healthcare & Board Secretary | $251,334.00 | — | 68 | $2,758.00 | 0.05% |
Elisa Michael Luqman | Chief Legal Officer of Healthcare & Board Secretary | $251,334.00 | — | 62 | $1,426.00 | 0.02% |
Jennifer Rodriguez | Investor & Public Relations Manager | — | — | — | — | — |
Vivian Sanders | Director of Marketing | — | — | — | — | — |
LaTanya Brackens | Director of Compliance | — | — | — | — | — |
Sarah Wallace | Director of Human Resources | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$148,237.22
Sells
0
$0.00
Net Sentiment
+$148,237.22
Net buying
Most Active
Jaumot Frank E
1 transactions
Analysis
Insiders reported 5 buys worth $148,237.22 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $148,237.22. Jaumot Frank E was the most active insider with 1 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | N/A4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Day One Biopharmaceuticals, Inc.
DAWN
$2.22B
Butterfly Network, Inc.
NYSE:BFLY
$1.91B
CareDx, Inc
NASDAQ:CDNA
$1.27B
AMN Healthcare Services, Inc.
NYSE:AMN
$1.20B
Replimune Group, Inc.
NASDAQ:REPL
$842.24M
HealthStream, Inc.
NASDAQ:HSTM
$748.20M
Ginkgo Bioworks Holdings, Inc.
NYSE:DNA
$578.78M
Evolent Health, Inc.
NYSE:EVH
$503.35M
Pacific Biosciences of California, Inc.
NASDAQ:PACB
$426.95M
Myriad Genetics, Inc.
NASDAQ:MYGN
$421.71M
Who manages NUTX?
Nutex Health, Inc. (NUTX) lists 11 active executives. The top listed executive is Pamela W. Montgomery, Chief Legal Officer of Healthcare & Board Secretary.
Are NUTX insiders buying or selling?
Recent insider activity shows net buying of $31.29B.
Explore More
Continue the stock analysis
Jump to another research area for this company.